A systematic review of Hepatitis B virus (HBV) prevalence and genotypes in Kenya: Data to inform clinical care and health policy

Louise O Downs[1,2], Cori Campbell[1], Paul Yonga[3], M. Azim Ansari[1],

Philippa C Matthews[1,4,5,6¶]* and Anthony O. Etyang[¶7]

[1] Nuffield Department of Medicine, Medawar Building for Pathogen Research, University of Oxford, South Parks Road, Oxford, UK

[2] Department of Infectious Diseases and Microbiology, John Radcliffe Hospital, Headley Way, Oxford, UK

[3] CA Medlynks Clinic and Laboratory, Nairobi, and Fountain Projects and Research Office, Fountain Health Care Hospital, Eldoret, Kenya

[4] The Francis Crick Institute, 1 Midland Way, London, UK

[5] Division of Infection and Immunity, University College London, London, London, UK

[6] Department of Infectious Diseases, University College London Hospital, London, London, UK

[7] KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

Key words: hepatitis B virus, HBV, epidemiology, serology, serosurveillance, prevalence, Kenya, Africa, genotype, drug resistance, treatment

* Corresponding author - Email: philippa.matthews@crick.ac.uk

¶These two authors contributed equally to this work

Abstract

More than 20% of the global disease burden from chronic hepatitis B infection (CHB) is in Africa, however there is minimal high quality seroprevalence data from individual countries and little viral sequencing data available to represent the continent. We undertook a systematic review of the prevalence and genetic data available for hepatitis B virus (HBV) in Kenya using the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) 2020 checklist. We identified 23 studies reporting HBV prevalence and 25 studies that included HBV genetic data published in English between January 2000 and December 2021. We assessed study quality using the Joanna Briggs Institute critical appraisal checklist. Due to study heterogeneity, we divided the studies to represent low, moderate, high and very high-risk for HBV infection. We calculated pooled HBV prevalence within each group and evaluated available sequencing data. We also assessed whether reported HBV biomarkers could be applied to determine treatment eligibility. Eight studies were identified in the low-risk group, seven in the moderate risk group, five in the high-risk group and three in the very high-risk group for HBV infection. Pooled HBV prevalence was 3.31% (95% CI 2.62-4.01%), 5.58% (95% CI 3.46-7.7%), 6.17% (95% CI 4.4-9.94) and 31.39% (95% CI 9.5-53.09) respectively. Study quality was overall low, representing a small geographical location or a limited population subset. Only three studies detailed sample size calculation and 17/23 studies were cross sectional. Eight studies included genetic information on HBV, representing 247 individuals. Six studies sequenced one or two genes; two undertook whole genome sequencing, representing 22 participants. 92% people were infected with genotype A. Other genotypes included genotype D (6%), D/E recombinants (1%) or mixed populations (1%). Drug resistance mutations were reported by two studies. Seven studies presented additional biomarkers

46   alongside HBsAg, however none provided sufficient information to deduce treatment

47   eligibility.

Introduction

Chronic hepatitis B (CHB) infection accounts for an estimated 90,000 deaths annually across

West, East and Southern Africa, where most countries are of medium to high prevalence for

CHB (prevalence ≥4%), accounting for around 20% of the worldwide burden of disease (1).

The World Health Organisation's (WHO) point prevalence estimate of CHB for Africa is 6.1%

with some uncertainty (4.6-8.5%), but this varies substantially between settings, and high-

quality data for individual countries are scarce (1). CHB meets many of the WHO criteria for a

neglected tropical disease, including disproportionately affecting populations living in

poverty, being associated with significant stigma and discrimination, and poor investment in

clinical infrastructure and research (2). Fewer than 10% of people have access to testing and

treatment leading to delayed diagnosis, with associated risks of advanced liver disease and

hepatocellular carcinoma (HCC) (1).

The Global Health Sector Strategy (GHSS) for viral hepatitis aims to eliminate HBV as a public

health threat by 2030 by reducing the incidence of new chronic infections by 90% and

reducing mortality by 65% from the 2015 baseline to achieve the 2030 WHO Sustainable

Development Goals (3). These are ambitious targets, and current estimates indicate they will

not be attained until beyond 2050 (4). Detailed seroprevalence data are needed to target

testing, treatment, and prevention interventions to the highest risk groups, to allocate

resources, and to inform policy.

In Kenya, information regarding HBV prevalence is lacking. Most studies focus on specific

groups such as blood donors and those living with HIV, which may not be representative of

the general population (5–7). Other studies have stringent inclusion criteria, meaning

important demographic subgroups remain uncharacterised (8). HBV testing is not done

routinely in Kenya, even in antenatal populations. Triple HBV vaccine from the age of 6 weeks

onwards is recommended by the Kenyan Ministry of Health as a component of the WHO

Expanded Programme for Immunization (EPI). It does not however currently recommend the

monovalent HBV vaccine at birth, due to a belief that HBV transmission in early life in Kenya

is horizontal rather than vertical, in which case birth dose vaccine would offer no significant

advantage over vaccination begun at 6 weeks (9). However, more data are needed to

underpin evidence-based policy in this domain.

HBV is divided into 9 genotypes (A-I) with a 10th putative genotype J (10,11); these tend to

have distinct geographical locations and have been linked to different outcomes. Genotype A

predominates in many African countries and has been associated with horizontal

transmission, chronicity, early HBeAg seroconversion (12), cirrhosis and HCC development

(13). Genotype also affects response to treatment (including drug resistance), and thus may

influence clinical recommendations (12–14), though is not yet widely undertaken in clinical

practice in most settings. Most studies of the impact of HBV genotype have been in Asia and

Europe. There is a paucity of data on circulating genotypes and subgenotypes in Africa,

including Kenya. Whole genome sequencing (WGS) of HBV in Kenya could provide

information on transmission networks, disease and treatment outcomes, drug resistance and

vaccine escape.

Guidelines for assessment and treatment of those with CHB typically involve complex

algorithms based on biomarkers such as quantitative HBV DNA, and liver stiffness scores

based on elastography (14) (Table 1). Regional African guidelines have been published (e.g.

by the South African Department of Health (15) and the Gastroenterology Society of Kenya

(16)). However, these still require a battery of tests on initial assessment and follow up, which

are not universally practical or accessible in many low- and middle-income country (LMIC)

settings. Thus, a refined assessment of population characteristics and needs is required to

help improve algorithms to better match the circumstances of the local population and to

support development of healthcare services.

Table 1: Recommendations by various international and national guidelines on assessment of a

person with chronic hepatitis B infection.

Summary of recommendations at diagnosis of CHB	EASL HBV Guidelines (20)	Kenyan HBV Guidelines (18)	NICE HBV Guidelines (UK) (17)	South African HBV Guidelines (19)
HBV serological markers				
FBC				
LFTs		+ aFP	+ aFP	
PTT				
Albumin				
Liver USS/ fibroscan				
Liver Biopsy				
Successive tests prior to treatment				

Red indicates not recommended for treatment decisions, orange indicates recommended if possible, green

indicates essential for treatment decision. HBV serological markers – HBsAg (Hepatitis B surface antigen), HBeAg

(Hepatitis B e-antigen), HBV DNA (quantitative viral load); FBC – Full blood count; LFTs – Liver function tests; aFP

= Alpha-fetoprotein; PTT – Prothrombin time; USS – Ultrasound scan; EASL – European Association for the Study

of the Liver; NICE – National Institute for Health and Care Excellence (UK).

We here assimilate data to describe the serological, clinical and molecular characteristics of

HBV infection in Kenya to underpin an evidence-base for local strategies for intervention, and

highlight knowledge gaps to inform research. High resolution local data will be essential for

development of local clinical care pathways and public health policy, to underpin progress

towards the 2030 elimination targets.

Methods

We set out to review literature on prevalence and genetic characteristics of HBV infection in

Kenya, using the Preferred Reporting Items for Systematic Review and Meta-analysis

(PRISMA) 2020 statement checklist (S1 Fig). We searched the online databases PubMed,

Embase, African Journals Online (AJOL) and Scopus on 6th December 2021 using the terms in

table 2. We included studies published in English, from 2000 to December 2021 (from 2003

for AJOL) that investigated prevalence, genotype and sequencing of HBV infection in Kenya.

We only included data for adults from studies for which the full text was available. There was

no minimum number of participants for studies included. We initially screened using a

thorough review of the title and abstract, and subsequently reviewed the full manuscripts of

eligible articles. Articles that did not meet the inclusion criteria were excluded. Any

uncertainty regarding the inclusion of papers was discussed with another reviewer and a

consensus obtained.

Table 2: Search terms for online databases used during a systematic review on HBV prevalence and genetic information in Kenya.

Database searched	Search terms
PubMed	(("Hepatitis B"[Mesh]) OR ("hepatitis b"[Title/Abstract] OR HBV[Title/Abstract] OR "hepatitis type b"[Title/Abstract] OR "type b hepatitis"[Title/Abstract] OR "hep b"[Title/Abstract])) AND (("Kenya"[Mesh]) OR (kenya*[Title/Abstract] OR nairobi*[Title/Abstract] OR mombasa*[Title/Abstract]))
Embase	1 exp hepatitis B/ (109266) 2 ("hepatitis b" or HBV or "hepatitis type b" or "type b hepatitis" or "hep b").ti,ab. (135330) 3 1 or 2 (161216) 4 Kenya/ (22999) 5 (Kenya* or nairobi* or mombasa*).ti,ab. (26384) 6 4 or 5 (29072) 7 3 and 6 (227) 8 limit 7 to yr="2000 -Current" (173)
AJOL	(("Hepatitis B" OR ("hepatitis b" OR HBV OR "hepatitis type b" OR "type b hepatitis" OR "hep b" AND (("Kenya") OR (Kenya* OR nairobi* OR mombasa*))
Scopus	(("Hepatitis B" OR ("hepatitis b" OR HBV OR "hepatitis type b" OR "type b hepatitis" OR "hep b" AND (("Kenya") OR (Kenya* OR nairobi* OR mombasa*))

Terms used to search online databases for a systematic review reporting prevalence and genetic data for HBV

in Kenya. We also modified search terms to include the 5 largest cities in Kenya (Nairobi, Mombasa, Eldoret,

Nakuru and Kisumu with no change to the results).

From each study, we extracted:

-    Total number of individuals tested for HBV.

-    Number of individuals found to be infected with HBV (either HBsAg positive or HBV

DNA positive)

-    Study location (city or geographical region)

-    Participant selection criteria

-    Laboratory methods for confirmation of HBV infection

-    Any other measurements taken relating to HBV assessment and liver health

-    Whether any viral sequencing was undertaken, methods used and results (including

genotype, presence of vaccine escape and drug resistance mutations).

Early in the review, it became obvious the studies would be very heterogenous. On these

grounds, we divided them into four groups to represent different risk profiles. The low-risk

group included studies most likely to represent the general population (antenatal women,

healthcare workers, blood donors and the national survey), the moderate risk group consisted

of studies containing populations living with HIV, the high-risk group included intravenous

drug users, men who have sex with men (MSM) and sex workers, and the very high-risk group

was those presenting to hospital with hepatitis or jaundice.

158 Quality assessment of studies

159 A thorough assessment of the study quality was done using the PRISMA guidelines (20) and

160 Joanna Briggs Institute critical appraisal checklist for prevalence studies (S2 Fig) (21). Any

161   dispute surrounding study quality was discussed with another reviewer and a consensus

162   reached.

Current available Kenyan full-length sequences

165   We downloaded all full genome HBV sequences from Kenya in GenBank on 1-December-2021

166   to assimilate a reference set of all whole genome sequences representing Kenya. Sequences

167   were aligned with available HBV reference sequences for each genotype (11) using MAFFT

168   (22). A maximum likelihood phylogenetic tree with bootstrap replicates of 1000 was created

169   using NGPhylogeny.fr (23)

Statistical Analysis

Pooled prevalence estimates for CHB infection (i.e. HBsAg seroprevalence) were generated

via meta-analysis using inverse-variance weighting of standard errors. Meta-analysis was

conducted in R (version 4.1.1) using the 'meta' package (version 5.2-1). Standard errors for

prevalence were calculated using the formula $\sqrt{p(1-p)/n}$, with the total sample size

represented by n and the proportion of the sample seropositive for HBV represented by p.

Meta-analysis was stratified by cohort risk group. The I^2 statistic was used to quantify the

heterogeneity between studies within each risk group, calculated using I^2 = 100% x (Q-df)/Q

where Q – Cochran's coefficient and df = degrees of freedom. Pooled estimates from fixed

and random effects models are presented for each risk group. Where heterogeneity was

statistically significant, results from random effects models were discussed. Study site

locations were identified using latitudinal and longitudinal data from Googlemaps based on

where the study was conducted. The map plot was created in R (version 4.1.1) using

'rworldmap' (verion 1.3-6) 'ggmap' (version 3) and 'ggplot2' (version 3.3.5) packages.

Occult HBV infection

187   Occult HBV infection (OBI) is defined as detectable HBV DNA in the absence of HBsAg. Where

188   studies reported both HBsAg positivity rates and OBI rates in those who were HBsAg negative,

189   only prevalence data based on HBsAg positivity was included in the meta-analysis, in order to

190   ensure datasets were comparable between studies.

Review of treatment guidelines

We reviewed clinical and laboratory data necessary to make HBV treatment decisions based

on the National Institute for Health and Care Excellence (NICE) (17), European Association for

the Study of the Liver (EASL) (24), National South African (19) and Kenyan guidelines (18) on

the management of CHB (Table 1). For each study reporting factors involved in treatment

decisions, we reviewed the information available and compared it to the treatment

guidelines. We then reviewed the proportion of study participants who would meet

treatment criteria by each of these guidelines.

Results

(i) Identification of Studies

We identified 272 published studies, of which 23 studies met the inclusion criteria,

representing a total of 11,467 people (Figure 1 and Table 3). Three of these studies also

screened individuals for occult HBV infection (OBI) in a total of 666 people using HBV DNA

polymerase chain reaction (PCR) in addition to testing for HBsAg seroprevalence. Two studies

screened initially with HBsAg, then with HBV DNA PCR on those who were HBsAg negative

(25,26). A further study included two different populations: a) those attending a clinic for sex

workers, whom they screened initially for HBsAg, then HBV PCR in those who were HBsAg

negative and b) known HBsAg negative, jaundiced participants whom they screened with HBV

DNA PCR to detect OBI (27).

Figure 1: Flow chart for eligibility of studies included in a systematic review reporting prevalence
and genetic data for HBV in Kenya between 2000 – 2021 (AJOL: African Journal Online).
Table 3: Characteristics of the studies included in the systematic review reporting prevalence and
genetic data for HBV in Kenya.

First Author	Year	N	Location	HBV +ve (%)	Data collection method	Study design	Sampling type	Population recruitment location	Population Investigated	Detection Method
Very high-risk populations (total 3 studies representing 492 individuals)										
Atina JO (28)	2004	60	Nairobi	30	Prospective	Cross sectional	Non-random	Hospital	Hepatitis	RPHA
Muchiri I (29)	2013	100	Nairobi	13	Prospective	Cross sectional	Non-random	Hospital	Hepatitis	RPHA
Ochwoto M (30)	2016	332	Nairobi, Mombasa, Kisumu Eldoret	50.6	Prospective	Cross sectional	Non-random	Hospital	Jaundiced	CLEIA
High risk populations (total 5 studies representing 2221 individuals)										
Day SL (7)	2013	159	Mombasa	7	Prospective	Cohort	Non-random	HIV clinic	Female sex workers	CLEIA
Webale MK (31)	2015	752	Mombasa	5.2	Retrospective	Cross sectional	Non-random	Community	Drug users	5 panel rapid test
Wahome E (32)	2016	525	Coastal Kenya	8	Retrospective	Cohort	Non-random	Community	HIV neg MSM	ELISA
Oyaro M (33)	2018	673	Nairobi, Mombasa, Kisumu	4.3	Prospective	Cross sectional	Non-random	Community	Drug users	ELISA
Jepkemei (27)	2020	112	Nairobi	9.8	Retrospective	Cohort	Non-random	Health clinic	MSM	CLEIA
Moderate risk populations (total 7 studies representing 1861 individuals)										
Harania RS (34)	2008	357	Nairobi	6.2	Prospective	Cross sectional	Non-random	HIV clinic	Adults HIV	ELISA
Kim HN (35)	2011	389	Nairobi	6.9	Retrospective	RCT	Random	HIV clinic	Adults HIV	ELISA
Muriuki BM (36)	2013	290	Nairobi	6.2	Prospective	Cross sectional	Non-random	HIV clinic	Adults HIV	ELISA
EN Njuguna (37)	2015	322	Nairobi, Thika	1	Prospective	Cross sectional	Random	HIV clinic	HIV discordant couples	ELISA
Maina DN (38)	2017	190	Kajiado	5.8	Prospective	Cross sectional	Non-random	HIV clinic	Adults HIV	CLEIA
Greer AE (39)	2017	105	Kisumu	11	Prospective	RCT	Non-random	HIV clinic	HIV discordant couples	CLEIA
Salyani A (26)	2021	208	Nairobi, Kijabe, Mbagathi	5.8	Prospective	Cross sectional	Non-random	HIV clinic	Adults HIV	CLEIA
Low risk populations (total 8 studies representing 6828 individuals)										
Ngaira JA (40)	2016	287	Mbagathi	3.8	Prospective	Cross sectional	Random	Antenatal clinic	Pregnant Women	ELISA
Ly KN (41)	2016	1091	Countrywide	2.1	Retrospective	2 stage cluster	Random	National survey	Urban and rural clusters	ELISA
Wamamba D (42)	2017	2046	Kisumu	3.1	Retrospective	Cross sectional	Non-random	Blood donor clinic	Blood Donors	ELISA
Onyango CG (43)	2018	1215	Kisumu, Siaya, Homa Bay	3.5	Prospective	Cross sectional	Random	Blood donor clinic	Blood Donors	ELISA
Bartonjo G (5)	2019	594	Nakuru, Tenwek	5.6	Prospective	Cross sectional	Random	Blood donor registry	Blood Donors	ELISA
Kisangau EN (44)	2019	295	Makueni	4.5	Prospective	Cross sectional	Random	Hospital rota	Healthcare workers	ELISA
Awili HO (45)	2020	1000	Kisumu, Siaya, Homa Bay	3.4	Prospective	Cross sectional	Non-random	Blood donor clinic	Blood Donors	ELISA
Aluora PO (25)	2020	300	Nairobi	2.3	Prospective	Cross sectional	Random	Blood donor clinic	Blood Donors	CLEIA
Studies of Known HBsAg positive people included for genetic data analysis (total 2 studies representing 90 individuals)										
Kwange SO (46)	2013	32	Nairobi	100	Retrospective	Cross sectional		Blood donor registry	Blood Donors	ELISA
Ochwoto (47)	2013	58	Nairobi	100	Prospective	Cross sectional		Blood donor registry	Blood Donors	ELISA
Studies Looking at Occult HBV Prevalence in HBsAg negative individuals (total 3 studies representing 666 individuals)										
Jepkemei (27)	2020	166	Nairobi	18.7	Retrospective on HBsAg -ve only	Cohort	Non-random	Health clinic	MSM/Jaundice	HBV DNA PCR
Salyani A (26)	2021	196	Nairobi, Kijabe, Mbagathi	5.3	Retrospective on HBsAg -ve only	Cross sectional	Non-random	HIV clinic	Adults HIV	HBV DNA PCR
Aluora PO (25)	2020	293	Nairobi	2.4	Retrospective on HBsAg -ve only	Cross sectional	Random	Blood donor clinic	Blood Donors	HBV DNA PCR

This includes two studies on solely HBsAg +ve patients used only for analysis of genetic data (46,47), and three
studies looking at OBI prevalence (25–27). Studies are ranked as very high / high / moderate / low risk groups
(presented in order) and within these categories ordered by date of publication.

N – number in the study; RCT – randomised controlled trial; RPHA – Reverse passive haemagglutination; CLEIA
– Chemiluminescent immunoassay; ELISA – enzyme linked immunosorbent assay; PCR – polymerase chain
reaction; HBsAg – Hepatitis B surface antigen; MSM – men who have sex with men.
223

We identified eight studies reporting HBsAg prevalence in low-risk populations (total number

of participants = 6828), seven studies in people living with HIV (medium risk, total number of

participants = 1861), five studies in high-risk groups (total number of participants = 2221) and

three studies in the very high-risk group (total number of participants = 492).

Two studies included only HBsAg positive participants (total sample size 90) and studied HBV

genotype (46,47). These were not included in our evaluation of HBV prevalence but

contributed to our appraisal of HBV sequencing data.

233 (ii) Geographical distribution of HBV seroprevalence data

Of the 23 studies included, 14 (61%) were in Nairobi or Mombasa, Kenya's most populous

cities (Table 3), and all studies were done in the South of the country along the infrastructure

routes between Mombasa, Nairobi and Kisumu. These are also the most densely populated

Kenyan counties (48). Kisumu was the city most represented in the studies by overall sample

size (Figure 2).

Figure 2: Map of Kenya indicating the locations and size of populations from which seroprevalence
of HBV infection is reported. Data from a systematic review of papers reporting prevalence and
genetic data for HBV in Kenya between 2000 and 2021. The size of the red circle indicates numbers
screened in each location, studies in the same location are grouped together. n = number of
individuals reported.

The mean cohort sample size was 599 participants (IQR 434)**.** 14 studies recruited participants

for cohort inclusion at outpatient clinics (8 in HIV clinics, 4 in blood donor clinics, 1 in a health

clinic and 1 in antenatal clinic), one recruited participants through the blood donor registry;

three through community outreach screening, three recruited hospital inpatients; one

recruited healthcare workers and one was a national survey using urban and rural population

groups (table 3).

253   (iii) Quality assessment of the literature

Overall the quality of studies investigating HBV prevalence in Kenya was low (Figure 3 and S2

Fig). 17/23 studies were cross sectional, reporting HBV population prevalence at a single time

point only. Most cohort sampling methods were non-randomised and only 4/21 studies

detailed their sample size calculation (25,26,40,44). Several studies sampled people only from

small geographical locations or from a subset of the general population e.g. HIV negative

individuals. 21/23 studies used either an enzyme linked immunosorbent assay or

chemiluminescent enzyme immunoassay (ELISA or CLEIA) for HBsAg diagnosis. Two studies

used reverse passive haemagglutination for diagnosis of CHB, a method previously

demonstrated to have poor sensitivity (28,29,49) (Table 3). 2/23 studies went on to screen

the HBsAg negative population for HBV DNA via PCR (25,26) and one study included a known

HBsAg negative population which they screened for HBV DNA (27).

Figure 3: Bar chart showing characteristics of studies identified for a systematic review reporting
prevalence and genetic data for HBV in Kenya. This is stratified by number of participants, study
design, sampling method, data collection and diagnostic methods. RCT: Randomised controlled trial;
EIA: Chemiluminescent enzyme immunoassay; ELISA: Enzyme linked immunosorbent assay.

(iv) Biomarkers measured and assessment of treatment criteria

Of the 23 studies examined, 12 reported solely HBsAg detection as a binary result (positive or negative) (table 4). Seven studies combined HBsAg testing with anti-HBc and/or anti-HBs to quantify HBV exposure and/or vaccination rates (7,26,27,31,32,39,41). The mean prevalence of anti-HBc alone or in combination with anti-HBs in those who were HBsAg negative was 38% indicating recovered infection. 4/7 studies reported prevalence of anti-HBs alone in those who were HBsAg negative, indicating likely vaccination, with a mean prevalence of 7.4% (26,31,32,39). Six studies reported HBeAg status and/or HBV DNA quantification (7,33–35,39,50). In those who were HBsAg positive, HBeAg positivity varied between studies from 55% in one study (7) to only 0.7% in another (50).

Table 4: HBV Biomarkers measured by studies reporting prevalence and genetic data for HBV in Kenya

Citation	HBsAg	Anti-HBc or Anti-HBs	HBeAg	ALT	HBV DNA PCR	Fib-4 or APRI	Any imaging (USS/elastography)
Very high-risk population group							
Atina JO (28)	▓			▓			
Muchiri I (29)	▓						
Ochwoto M (30)	▓						
High risk population group							
Day SL (7)	▓	▓	▓		▓		
Webale MK (31)	▓	▓	▓				
Wahome E (32)	▓	▓					
Oyaro M (33)	▓				▓		
Jepkemei (27)	▓	▓					
Moderate risk population group							
Harania RS (34)	▓		▓		▓		
Kim HN (35)	▓			▓	▓		
Muriuki BM (36)	▓						
EN Njuguna (37)	▓						
Maina DN (38)	▓						
Greer AE (39)	▓	▓	▓		▓		
Salyani A (26)	▓	▓					
Low risk population group							
Ngaira JA (40)	▓						
Ly KN (41)	▓	▓					

Wamamba D (42)							
Onyango CG (43)							
Bartonjo G (5)							
Kisangau EN (44)							
Awili HO (45)							
Aluora PO (25)							

A blue square indicates the biomarker was measured in that study. ALT – Alanine aminotransferase; USS –

ultrasound, Fib-4 and APRI are non-invasive scores of liver health accredited by the World health Organisation

for the assessment of patients with chronic hepatitis B (51) .

Seven studies which measured additional biomarkers alongside HBsAg or anti-HBc/anti-HBs

(including HBeAg, HBV DNA and/or liver function tests) were assessed to determine whether

participants met local or international HBV treatment guidelines (table 5). Three studies did

not present sufficient information to assess treatment eligibility (26–28). Of the remaining

four studies representing 167 HBsAg positive participants, 32/167 (19%) people would have

possibly met EASL treatment criteria alone if they were aged >30 years, however line-level

age data were not presented, so this could not be confirmed. A further 14/167 (8%)

participants may have met EASL, South African and Kenyan treatment criteria as they had

abnormal ALT alongside HBeAg positivity and high HBV viral load. However, there was

insufficient data on the level of ALT derangement to fully determine this. We were unable to

assess whether any individuals met criteria for therapy based on NICE guidelines, as these

require longitudinal follow up with serial biomarker monitoring.

Table 5: Studies assessed for participants meeting treatment criteria of the NICE, EASL, South African

(SA) or Kenyan HBV treatment guidelines as part of a systematic review reporting prevalence and

genetic data for HBV in Kenya.

Population Risk Group	Citation	Consideration of meeting national and international treatment criteria
Moderate risk for HBV infection - HIV coinfection	Kim HN (35)	27 HBsAg +ve participants 3/27 would meet EASL treatment criteria if >30 years

Moderate risk for HBV infection - HIV coinfection	Greer AE (39)	106 HBsAg +ve. 23/106 would meet EASL treatment criteria if >30 years
Moderate risk for HBV infection – HIV coinfection	Harania RS (34)	23 HBsAg +ve participants 11 could have met treatment criteria based on EASL, South African and Kenyan guidelines depending on level of ALT derangement.
High risk for HBV infection – Female sex workers	Day SL (7)	11 HBsAg +ve participants 6/11 Would have met EASL treatment criteria if aged >30 years 3/11 meet EASL, South African and Kenyan guidelines (although Kenyan guidelines recommend successive measurements).
High risk for HBV infection – Drug users	Oyaro M (33)	Measured HBV DNA but results not presented. No HBeAg data. Unable to assess whether meet treatment criteria.
High risk for HBV infection – Drug users	Webale MK (50)	30 HBsAg +ve participants. 1 was HBeAg +ve but nil on HBV DNA or liver disease Unable to assess whether meet treatment criteria.
Very high risk for HBV infection – those presenting to hospital with hepatitis	Atina JO (28)	No information on HBeAg status. ALT not distinguished between patients infected with different hepatitis viruses. Unable to assess whether meet treatment criteria.

304 HBsAg – hepatitis B surface antigen; HBeAg – hepatitis B e antigen; EASL – European association for the study of
305 the liver; ALT – Alanine aminotransferase.

307 (v) HBV prevalence estimates in different risk groups

The pooled estimate for HBV prevalence using a random effects model in the low-risk group

was 3.31% (95% CI 2.62-4.01%) compared with 5.58% in the moderate risk group (95% CI

3.46-7.7%), 6.17% (95% CI 4.4-7.94%) in the high-risk group and 31.29% (95% CI 9.5-53.09%)

in the very high-risk group, however we note that the confidence interval of this estimate is

very wide (Figure 4). Heterogeneity was significant ($I^2 > 50\%$) within each subgroup, and

highest in the very high-risk sub-group ($I^2 = 97\%$, $p < 0.01$).

Three studies screened for OBI using HBV DNA PCR. These were in populations known to be

HBsAg negative and from different HBV risk groups: blood donors, those living with HIV and

those presenting to hospital with jaundice. OBI prevalence estimates in these studies were

2.4%, 5.3% and 18.7% respectively (25,52,53).

Figure 4: Forest plot showing pooled HBV prevalence for populations in different risk groups by fixed

and random effects model. This is part of a systematic review reporting prevalence and genetic data

for HBV in Kenya between 2000-2021. In each case, the size of the population included is represented

by the size of the square. Point prevalence and 95% Confidence Interval (CI) is indicated for each study.

Studies are ordered by HBV prevalence in each risk group.

326   (vi) Identification of HBV sequences

We identified nine studies in total reporting HBV sequence data (full or partial genome),

including seven studies from among our 23 seroprevalence studies (Table 3), and an

additional two studies that did not contribute to the prevalence estimates (46,47), providing

a total of nine studies representing 247 individuals. One study did not clearly report how

many HBV samples were sequenced or what the results were, and this study was

subsequently excluded from further analysis (39). All the eight remaining studies used PCR of

the HBV basal core promotor, Pol or S genes for amplification, followed by Sanger sequencing

to determine genotype. Two studies looked for known drug resistance mutations (46,47). Two

studies undertook whole genome HBV sequencing in a total of 22 patients (30,46). 228/247

(92%) of participants were infected with HBV genotype A, 15/247 (6%) with genotype D

infection, whilst the remaining were either mixed genotype populations (2/247) or genotype

D/E recombinants (2/247) (table 6). Sub-genotype was determined in 146/247 (59%)

participants. This was most commonly sub-genotype A1 (134/146, 92%) in keeping with

previous regional data (54).

Table 6: Numbers of individuals in which HBV genotype or sub-genotype was reported for study populations in Kenya, as part of a systematic review on prevalence and genetic data for HBV in Kenya from 2000 – 2021.

Genotype	Sub-genotype	Number of individuals
A (total 228)	Not sub-genotyped	94
	A1	134
D (total 15)	Not sub-genotyped	3
	D3	3
	D4 or D6	9
D/E Recombinants		2
Unclear		2

To provide further background context for HBV sequences in Kenya, we identified 25 full length HBV sequences from GenBank (Figure 5). These were generated from three studies, published in 2013, 2015 and 2016 (30,47,55). They primarily represented individuals presenting to hospital with jaundice, (21/25 sequences) infected with genotypes A1 and D.

Figure 5: Maximum likelihood phylogenetic tree of full-length consensus HBV sequences from Kenya. Kenyan sequences are those published in GenBank (downloaded 1st Dec 2021) and are shown in red alongside genotype reference sequences in black (1000 bootstrap replicates were performed, and bootstrap support of ≥70% are indicated. Reference sequences from McNaughton et al. (2020) (11).

5/8 studies provided a detailed analysis of either amino acid or nucleotide substitutions found in the sequenced region of HBV (25,30,35,46,47). 2/5 studies correlated these with known drug resistance mutations to lamivudine and other nucleoside analogues (Table 7) (25,35). One study reported the emergence of drug resistance mutations during lamivudine treatment associated with breakthrough HBV viraemia (35). Multiple other mutations were described in the five studies, some of which were in the major hydrophilic region of the surface gene, and

362   thus potentially important in influencing both natural and vaccine-mediated immunity

363   (56,57).

365   **Table 7: Details of HBV mutations found in two studies in Kenya which reported presence of drug**

366   **resistance mutations, as part of a systematic review on prevalence and genetic data for HBV in**

367   **Kenya from 2000 – 2021.**

First Author	Publication Year and number of participants	Mutations Identified	Number of individuals with mutation	Resistance conferred
Kim HN (35)	2011 (n=389) 21 participants had HBV sequenced	rt1233V rtA181S rtV207I	3/21 had rt1233V, rtA181S or rtV207I prior to treatment	Adefovir + lamivudine
		A200V M204I	1/21 developed A200V + M204I during lamivudine treatment	Lamivudine
		M204I	1/21 developed M204I during lamivudine treatment	Lamivudine
Patrick Okoti Aluora (25)	2020 (n=300) 9 participants had HBV sequenced (2 HBsAg +ve, 7 HBV DNA +ve only)	rt181T	1/9	Lamivudine, Adefovir
		M129L V163I	9/9	Lamivudine

368   In Kim HN, two patients developed HBV breakthrough viraemia during lamivudine treatment and developed

369   either RT M204I mutation alone or both A200V and M204I mutations during treatment.

Discussion

Enhanced efforts to characterise the epidemiology and disease burden of HBV are urgently

required in Africa, as HBV is present at medium-high endemicity in many populations but has

been neglected as a public health problem. Here we have reviewed the literature available

on prevalence, genotypes and available sequence data for CHB in Kenya. The pooled

prevalence estimates we generated in the different risk groups ranged from 3.31% in the low

risk group to 31.29% in the very high-risk group, although wide confidence intervals along

with significant heterogeneity (I^2 = 97%) are notable in the very high risk group. This is the

group presenting to hospital with jaundice or hepatitis who are likely to have very different

pre-test probabilities for HBV infection.

Most studies included in this review focussed on specific groups of people such as blood

donors and those co-infected with HIV. Blood donation in Kenya is voluntary and often done

by family members of those in need. There is no financial compensation for donation (58).

Routine screening for HBV through the Kenyan National Blood Transfusion Service (KNBTS)

consists of ELISA for HBsAg only and there is no nucleic acid amplification testing (NAAT);

some OBI may therefore go unidentified. Only one study in this review focussed on pregnant

women (40) and one study enrolled healthcare workers (44). These are accessible and

important groups to screen for HBV infection given they are engaged with healthcare, likely

to come for follow up visits, and interventions can have a significant impact on reducing

transmission events. Treatment for pregnant mothers and healthcare workers would reduce

onward transmission, and vaccination of babies and uninfected healthcare workers would

decrease the overall burden of infection, reducing morbidity and mortality. One study was

nationwide (41), but only included those who were HIV negative. More general population

screening is lacking, and testing is not routinely done when presenting to healthcare facilities

(59). Some areas of the country have been more rigorous in their diagnostic approaches, but

this is sporadic and may be increased only when there is a known outbreak of HBV in the local

community, as has been the case in other African countries (60,61). This may give a skewed

view on population prevalence, but also leads to missed opportunities for diagnosis and

intervention, particularly given the very high proportion of those presenting to hospital with

jaundice or hepatitis found to be infected with HBV (pooled HBV prevalence 31.29% and

18.7% OBI prevalence).

It is notable that no studies were done in Northern Kenya, particularly along the borders with

Somalia and South Sudan where the prevalence of HBV is substantially higher (for these two

neighbouring countries, HBsAg prevalence estimated at 19% and 12% respectively (62,63)),

however population density here is also very low (48).

Along with minimal population screening, there is very little sequencing of HBV in Kenya. Of

the 25 papers we reviewed regarding HBV sequencing, only two reported whole genome

sequencing, and none did next generation sequencing. We identified only 25 complete HBV

genomes from Kenya in a GenBank search. Most available data is from single gene PCR and

Sanger sequencing of S and P genes to determine genotype. Expanding these data will allow

identification of recombinant genotypes, of which there is evidence in Kenya (64,65), but

currently without good understanding of how these translate into clinical outcomes. Deep

sequencing data will enable detection of minority variant mutations that may be relevant in

emergence of vaccine escape and drug resistance, and also allow description of viral

quasispecies, how this correlates with clinical phenotype and other biomarkers.

Three studies reviewed here screened for OBI using PCR. OBI prevalence was similar to

estimated pooled HBsAg prevalence in the associated risk group (2.4%, 5.3% and 18.7% OBI

prevalence in low, medium and high/very-risk groups compared with 3.31%, 5.58% and

6.17/31.29% pooled HBsAg positivity estimates in the equivalent groups). This indicates that

many HBV cases are being missed due to the lack of appropriate screening tests, however the

cost and poor availability of HBV DNA testing means it is not currently feasible to use as a

universal screening test in Kenya. 20/23 studies solely reported HBsAg positivity diagnosed

using other less sensitive tests. It is worth noting that of those presenting to hospital with

jaundice who were HBsAg negative, nearly 20% were HBV DNA positive. It is not known

whether the jaundice was due to acute HBV infection, or reactivation of chronic disease, but

it seems to be an important indicator of HBV infection and screening of all those presenting

to hospital with jaundice or hepatitis for OBI with HBV DNA PCR would be optimal. Few

studies had characterised HBV exposure and vaccination status using anti-HBc and anti-HBs

respectively. This highlights a broader issue around funding and access to laboratory tests

needed for complete epidemiological assessment of populations.

Comparing data available within these studies to a range of African and European treatment

algorithms highlights the complexity of guidelines. Most of the studies we included had not

been set up to include assessment of treatment criteria, which was likely not feasible within

the setting of the study. However, measurement of parameters such as HBeAg, HBV DNA viral

load, and liver elastography are clearly outside the reach of existing budgets and

infrastructure, and we highlight the need for simpler treatment stratification and cost

effectiveness analysis for Kenya and other LMIC settings.

444   HIV coinfection as a special case

The prevalence of HIV infection in adults in Kenya is 4.2% (95% CI 3.7-4.9%) (66). Seven studies

included in this analysis reported HBV prevalence in people living with HIV. The pooled HBV

prevalence in this group was 5.58% (95% CI 3.46 − 7.7%). The HIV population is better

represented than other groups at risk, as HBV screening is easier to offer to individuals already

accessing healthcare for HIV monitoring and treatment. Through this established

infrastructure for HIV (including clinics with staff, laboratory support, blood monitoring and

drug distribution services), clinical care pathways for HBV could be incorporated. Although

tenofovir is available free of charge in Kenya, and is on the WHO list of essential medicines

(67), it is only consistently available in combination with lamivudine or emtricitabine for HIV

treatment, leaving the HBV monoinfected population unable to access licensed monotherapy.

456   Limitations

The HBV prevalence estimates we have generated here are wide and vary significantly

between the risk groups (pooled risk group prevalence 3.31% - 31.29%). The very high-risk

group also has a very wide confidence interval for prevalence estimates. Other sources have

different estimates of Kenyan HBV prevalence (e.g. 1% by the CDA Foundation (4)). The CDA

data are from 2016, so may be out of date, but the varying estimates reflect difficulties with

methods of data collection, varying data sources and data missingness. The overall quality of

studies was low, with non-random sample selection common, no calculation of sample size

in most studies and nearly all studies being cross sectional representing only a snapshot of

HBV prevalence. Only selected populations are represented by the studies we identified, and

even those studies seeming to represent the population more broadly are skewed. For

example, the study of healthcare workers was primarily female nurses (44) and the

nationwide survey only included HIV negative participants (41). OBI was investigated in only

three studies. There are no data for the northern part of Kenya, including the region around

the border with South Sudan where there might be migration of high prevalence populations.

It is likely that prevalence of HBV infection varies significantly by age, region of the country,

and according to particular at-risk groups – thus targeted surveillance is important to provide

an evidence-base for local and population-specific interventions.

No children were included in this review. In 2019 Kenya achieved an average coverage of 91%

of 3rd dose HBV childhood vaccination (68), but in future studies, screening children for HBsAg,

anti-HBc, anti-HBs by birth cohort would be important to determine the impact of the vaccine

campaign on infection, exposure and immunity, and to identify any populations being missed

by vaccine coverage. More evidence is needed to determine whether birth dose HBV

immunisation should be routinely deployed.

We highlight the poor representation of HBV in Kenya with sequencing data, identifying only

two studies that undertook whole genome sequencing. 24/25 sequences available on

GenBank were from two studies. This is clearly not representative of HBV in the general

population, and work is required to determine circulating genotypes and to characterise

polymorphisms that are relevant to outcomes of infection, treatment and vaccination.

Conclusions

We have assimilated epidemiological data for HBV in Kenya, together with clinical and genetic

parameters where available, to provide the most refined picture possible to date. A sparse

literature highlights the pressing need for clinical and research enterprise, to provide an

evidence base for realistic and practical strategies that support country-specific scale-up of

screening and treatment. Alongside continued efforts for three-dose vaccine coverage in

infancy, these interventions can reduce the burden of disease in those currently infected, and

reduce the incidence of new infections, moving Kenya towards 2030 elimination targets.

Registration and Protocol

This was not registered as a systematic review. A review protocol was prepared in advance

but not published.

Funding

LD is funded by a Wellcome Clinician PhD fellowship. CC is funded by GlaxoSmithKline (GSK)

and the University of Oxford Nuffield Department of Medicine. PCM is funded by a Wellcome

intermediate fellowship (ref 110110Z), UCL/UCLH BRC and the Francis Crick Institute.

Acknowledgements

This manuscript was written with the permission of the Director, KEMRI-CGMRC

Conflicts

CC (supervised by PCM) receives a contribution of her PhD fellowship funding from GSK.

References

1. World Health Organisation. Global hepatitis report, 2017. 2017.

2. O'Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R, et al. Hepatitis B virus infection as a neglected tropical disease. PLoS Neglected Tropical Diseases. 2017 Oct 5;11(10).

3. WHO. Global health sector strategy on viral hepatitis 2016-2021. Global Hepatitis Programme Department of HIV/AIDS [Internet]. 2016 [cited 2021 Nov 9];(June):56. Available from: https://www.who.int/publications/i/item/WHO-HIV-2016.06

4. Countries Dashboard – CDA Foundation [Internet]. [cited 2022 Feb 7]. Available from: https://cdafound.org/polaris-countries-dashboard/

5. Bartonjo G, Oundo J, Ng'ang'a Z. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at regional blood transfusion center nakuru and tenwek mission hospital, Kenya. Pan African Medical Journal. 2019;34.

6. Otedo AEO. HBV, HIV co-infection at Kisumu District Hospital, Kenya. East African Medical Journal. 2004;81(12):626–30.

7. Day SL, Odem-Davis K, Mandaliya KN, Jerome KR, Cook L, Masese LN, et al. Prevalence, Clinical and Virologic Outcomes of Hepatitis B Virus Co-Infection in HIV-1 Positive Kenyan Women on Antiretroviral Therapy. PLoS ONE. 2013 Mar 18;8(3).

8. Kafeero HM, Ndagire D, Ocama P, Kudamba A, Walusansa A, Sendagire H. Prevalence and predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a systematic review and meta-analysis of epidemiological studies published from 2005 to 2020. Archives of Public Health. 2021 Dec 1;79(1).

9.   Ministry of Health. Kenya, National Policy Guidelines on Immunization 2013. 2013. 20

p.

10.   McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, et al. Insights

From Deep Sequencing of the HBV Genome—Unique, Tiny, and Misunderstood.

Gastroenterology. 2019;156(2):384–99.

11.   Mcnaughton AL, Revill PA, Littlejohn M, Matthews PC, Ansari MA. Analysis of genomic-

length HBV sequences to determine genotype and subgenotype reference sequences.

Journal of General Virology. 2020;101:271–83.

12.   Ito K, Yotsuyanagi H, Yatsuhashi H, Karino Y, Takikawa Y, Saito T, et al. Risk factors for

long-term persistence of serum hepatitis B surface antigen following acute hepatitis B

virus infection in Japanese adults. Hepatology [Internet]. 2014 Jan 1 [cited 2021 Nov

30];59(1):89–97.   Available   from:

https://onlinelibrary.wiley.com/doi/full/10.1002/hep.26635

13.   Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances

[Internet]. Vol. 26, Journal of Gastroenterology and Hepatology (Australia). John Wiley

&   Sons,   Ltd;   2011   [cited   2021   Nov   23].   p.   123–30.   Available   from:

https://onlinelibrary.wiley.com/doi/full/10.1111/j.1440-1746.2010.06541.x

14.   Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL

2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

Journal of Hepatology. 2017;67(2):370–98.

15.   Spearman CWN, Sonderup MW, Botha JF, van der Merwe SW, Song E, Kassianides C,

et al. South African guideline for the management of chronic hepatitis B: 2013. South

African Medical Journal. 2013;103(5):335–49.

16.   Government of Kenya, Gastroenterology Society of Kenya. Guidelines for the

559   Treatment of Chronic Hepatitis B and C Viral Infections in Kenya Gastroenterology

560   Society of Kenya Republic of Kenya. 2016.

561   17.   National Clinical Guideline Centre Hepatitis B (chronic) Diagnosis and management of

562   chronic hepatitis B in children, young people and adults Clinical guideline Methods,

563   evidence and recommendations [Internet]. 2013 [cited 2019 Apr 9]. Available from:

564   https://www.nice.org.uk/guidance/cg165/evidence/full-guideline-pdf-190175005

565   18.   Government of Kenya, Gastroenterology Society of Kenya. Guidelines for the

566   Treatment of Chronic Hepatitis B and C Viral Infections in Kenya Gastroenterology

567   Society of Kenya Republic of Kenya [Internet]. 2016 [cited 2021 Nov 30]. Available

568   from: kenya-national-hepatitis-guidelines-2014.pdf

569   19.   Spearman CWN, Sonderup MW, Botha JF, van der Merwe SW, Song E, Kassianides C,

570   et al. South African guideline for the management of chronic hepatitis B: 2013. South

571   African Medical Journal [Internet]. 2013 [cited 2021 Mar 9];103(5):335–49. Available

572   from: http://www.samj.org.za/index.php/samj/article/view/6452/5035

573   20.   PRISMA 2020 Checklist Section and Topic Item # Checklist item Location where item is

574   reported TITLE Title 1 Identify the report as a systematic review. [cited 2022 Feb 16];

575   Available from: http://www.prisma-statement.org/

576   21.   Munn Z, MClinSc SM, Lisy K, Riitano D, Tufanaru C. Methodological guidance for

577   systematic reviews of observational epidemiological studies reporting prevalence and

578   cumulative incidence data. International Journal of Evidence-Based Healthcare

579   [Internet]. 2015 Sep 1 [cited 2022 Mar 28];13(3):147–53. Available from:

580   https://journals.lww.com/ijebh/Fulltext/2015/09000/Methodological_guidance_for_

581   systematic_reviews_of.6.aspx

22. Katoh K, Rozewicki J, Yamada KD. MAFFT online service: multiple sequence alignment,

interactive sequence choice and visualization. 2019 [cited 2022 Apr 2];20(4):1160–6.

Available from: https://academic.oup.com/bib/article/20/4/1160/4106928

23. Fr´ F, Fréd´ F, Lemoine F, Correia D, Lefort V, Doppelt-Azeroual O, et al. NGPhylogeny.fr:

new generation phylogenetic services for non-specialists. Web Server issue Published

online [Internet]. 2019;47. Available from: http://www.atgc-montpellier.fr/presto

24. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL

2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

Journal of Hepatology [Internet]. 2017;67(2):370–98. Available from:

https://www.easl.eu/medias/cpg/management-of-hepatitis-B-virus-infection/English-

report.pdf

25. Aluora PO, Muturi MW, Gachara G. Seroprevalence and genotypic characterization of

HBV among low risk voluntary blood donors in Nairobi, Kenya. Virology Journal. 2020

Dec 1;17(1).

26. Salyani A, Shah J, Adam R, Otieno G, Mbugua E, Shah R. Occult hepatitis B virus

infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults. PLoS

ONE. 2021 Jan 1;16(1 January).

27. Jepkemei KB, Ochwoto M, Swidinsky K, Day J, Gebrebrhan H, McKinnon LR, et al.

Characterization of occult hepatitis B in highrisk populations in Kenya. PLoS ONE. 2020

May 1;15(5).

28. Atina JO, Ogutu EO, Hardison WG, Mumo J. Prevalence of hepatitis A, B, C and human

immunodeficiency virus seropositivity among patients with acute icteric hepatitis at

the Kenyatta National Hospital, Nairobi. East African Medical Journal [Internet]. 2004

Aug 20 [cited 2021 Nov 9];81(4):183–7. Available from:

https://www.ajol.info/index.php/eamj/article/view/9152

29. Muchiri I, Okoth FA, Ngaira J, Tuei S. Seroprevalence of HAV, HBV, HCV, and HEV among

acute hepatitis patients at Kenyatta National Hospital in Nairobi, Kenya. East African

Medical Journal [Internet]. 2013 Aug 1 [cited 2021 Dec 2];89(6):199–205. Available

from: https://www.ajol.info/index.php/eamj/article/view/91508

30. Ochwoto M, Kimotho JH, Oyugi J, Okoth F, Kioko H, Mining S, et al. Hepatitis B infection

is highly prevalent among patients presenting with jaundice in Kenya. BMC Infectious

Diseases. 2016 Mar 1;16(1).

31. Kilongosi MW, Budambula V, Lihana R, Musumba FO, Nyamache AK, Budambula NLM,

et al. Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected

injection and Non-injection drug users from coastal Kenya. BMC Infectious Diseases

[Internet]. 2015 Jul 30 [cited 2022 Feb 17];15(1):1–8. Available from:

https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-015-1060-3

32. Wahome E, Ngetsa C, Mwambi J, Gelderblom HC, Manyonyi GO, Micheni M, et al.

Hepatitis B Virus Incidence and Risk Factors Among Human Immunodeficiency Virus-1

Negative Men Who Have Sex With Men in Kenya. Open Forum Infectious Diseases.

2017 Jan 1;4(1).

33. Oyaro M, Wylie J, Chen CY, Ondondo RO, Kramvis A. Human immunodeficiency virus

infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-

infections among drug users in three major Kenyan cities. Southern African Journal of

HIV Medicine. 2018;19(1).

34. Harania RS, Karuru J, Nelson M, Stebbing J. HIV, hepatitis B and hepatitis C coinfection

in Kenya. AIDS. 2008 Jun 19;22(10):1221–2.

35. Kim HN, Scott J, Cent A, Cook L, Morrow RA, Richardson B, et al. HBV lamivudine

resistance among hepatitis B and HIV coinfected patients starting lamivudine,

stavudine and nevirapine in Kenya. Journal of Viral Hepatitis. 2011 Oct;18(10).

36. Muriuki BM, Gicheru MM, Wachira D, Nyamache AK, Khamadi SA. Prevalence of

hepatitis B and C viral co-infections among HIV-1 infected individuals in Nairobi, Kenya.

BMC Research Notes [Internet]. 2013 Sep 9 [cited 2022 Feb 8];6(1):1–6. Available from:

https://bmcresnotes.biomedcentral.com/articles/10.1186/1756-0500-6-363

37. Njuguna EN, Kinuthia PN, Kinoti M, of Public Health S, Kiarie J. Prevalence and risk

factors of previous or active Hepatitis B infection among HIV-1 discordant heterosexual

couples. East African Medical Journal [Internet]. 2015 Dec 9 [cited 2021 Dec

2];92(10):488–94. Available from:

https://www.ajol.info/index.php/eamj/article/view/127082

38. Maina D, Karen Hospital T, Kimang AN, Mwangi J, Mutai K, Lihana RW. Genotypes of

HBV and HCV among HIV-1 co-infected individuals in Ngong Sub-County, Kenya. East

African Medical Journal [Internet]. 2017 Mar 30 [cited 2021 Dec 2];93(12):640–5.

Available from: https://www.ajol.info/index.php/eamj/article/view/153976

39. Greer AE, Ou SS, Wilson E, Piwowar-Manning E, Forman MS, McCauley M, et al.

Comparison of hepatitis b virus infection in HIV-infected and HIV-uninfected

participants enrolled in a multinational clinical trial: HPTN 052. Journal of Acquired

Immune Deficiency Syndromes. 2017;76(4):388–93.

40. Malungu Ngaira JA, Kimotho J, Mirigi I, Osman S, Ng'ang'a Z, Lwembe R, et al.

Prevalence, awareness and risk factors associated with hepatitis b infection among

pregnant women attending the antenatal clinic at mbagathi district hospital in Nairobi,

Kenya. Pan African Medical Journal. 2016 Aug 17;24.

41.   Ly KN, Kim AA, Umuro M, Drobenuic J, Williamson JM, Montgomery JM, et al.

Prevalence of hepatitis B Virus infection in Kenya, 2007. American Journal of Tropical

Medicine and Hygiene. 2016 Aug 1;95(2):348–53.

42.   Wamamba D, Onyango D, Oyugi E, Kanyina E, Obonyo M, Githuku J, et al. Transfusion

transmissible infections among walk-in blood donors at Kisumu regional blood

transfusion centre, Kisumu County, Kenya, 2015. Lab Medicine. 2017 Nov 1;48(4):362–

6.

43.   Onyango KO, Nyamache AK, Kasera GO, Mabeya SN, Nonoh JO. Hepatitis B and C virus

co-infections and genetic diversity among HIV-1 infected individuals in Siaya County,

Kenya. East African Medical Journal [Internet]. 2021 May 21 [cited 2021 Dec

2];98(2):3508–18.   Available   from:

https://www.ajol.info/index.php/eamj/article/view/207458

44.   Kisangau EN, Awour A, Juma B, Odhiambo D, Muasya T, Kiio SN, et al. Prevalence of

hepatitis B virus infection and uptake of hepatitis B vaccine among healthcare workers,

Makueni County, Kenya 2017. Journal of Public Health (United Kingdom). 2019 Dec

1;41(4):765–71.

45.   Awili HO, Gitao GC, Muchemi GM. Seroprevalence and Risk Factors for Hepatitis B Virus

Infection in Adolescent Blood Donors within Selected Counties of Western Kenya.

BioMed Research International. 2020;2020.

46.   Kwange SO, Budambula NLM, Kiptoo MK, Okoth F, Ochwoto M, Oduor M, et al.

Hepatitis B virus subgenotype A1, occurrence of subgenotype D4, and S gene

mutations among voluntary blood donors in Kenya. Virus Genes [Internet]. 2013 Dec 5

[cited   2022   Jan   31];47(3):448–55.   Available   from:

https://link.springer.com/article/10.1007/s11262-013-0976-1

47.   Ochwoto M, Chauhan R, Gopalakrishnan D, Chen CY, Ng'ang'a Z, Okoth F, et al.

Genotyping and molecular characterization of hepatitis B virus in liver disease patients

in Kenya. Infection, Genetics and Evolution. 2013 Dec 1;20:103–10.

48.   2019 Kenya Population and Housing Census Volume I: Population by County and Sub-

County - Kenya National Bureau of Statistics [Internet]. [cited 2022 Mar 15]. Available

from: https://www.knbs.or.ke/?wpdmpro=2019-kenya-population-and-housing-

census-volume-i-population-by-county-and-sub-county

49.   Barbara JAJ, Harrison PJ, Howell DR, Cleghorn TE, Dane DS, Briggs M, et al. A sensitive

single reverse passive haemagglutination test for detecting both HBsAg and anti-HBs.

Journal   of   Clinical   Pathology   [Internet].   1979;32:1180–3.   Available   from:

http://jcp.bmj.com/

50.   Kilongosi MW, Budambula V, Lihana R, Musumba FO, Nyamache AK, Budambula NLM,

et al. Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected

injection and Non-injection drug users from coastal Kenya. BMC Infectious Diseases

[Internet].   2015   Jul   30   [cited   2022   Jan   31];15(1):1–8.   Available   from:

https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-015-1060-3

51.   GUIDELINES FOR THE PREVENTION, CARE AND TREATMENT OF PERSONS WITH

CHRONIC HEPATITIS B INFECTION. 2015;

52.   Salyani Id A, Shah J, Adam R, Otieno G, Mbugua E, Shah R. Occult hepatitis B virus

infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults. 2021;

Available from: https://doi.org/10.1371/journal.pone.0244947

53.   Jepkemeiid KB, Ochwoto M, Swidinsky K, Day J, Gebrebrhan H, Mckinnon LR, et al.

Characterization of occult hepatitis B in high-risk populations in Kenya. 2020 [cited

2022 Feb 16]; Available from: https://doi.org/10.1371/journal.pone.0233727.t001

54.   Rajoriya N, Combet C, Zoulim F, Janssen HLAA. How viral genetic variants and

genotypes influence disease and treatment outcome of chronic hepatitis B. Time for

an individualised approach? 2017 Dec 1;67(6):1281–97.

55.   Kibaya R, Lihana R, Kiptoo M, Songok E, Ng'ang'a Z, Osman S, et al. Characterization of

HBV Among HBV/HIV-1 Co-Infected Injecting Drug Users from Mombasa, Kenya.

Current HIV Research. 2015 Jun 19;13(4):292–9.

56.   Wu C, Zhang X, Tian Z, Song J, Yang D, Roggendorf M, et al. Biological significance of

amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation,

secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication.

J Gen Virol [Internet]. 2010 [cited 2022 Feb 9];91(Pt 2):483–92. Available from:

https://pubmed.ncbi.nlm.nih.gov/19812261/

57.   Tian Y, Xu Y, Zhang Z, Meng Z, Qin L, Lu M, et al. The Amino Acid Residues at Positions

120 to 123 Are Crucial for the Antigenicity of Hepatitis B Surface Antigen. JOURNAL OF

CLINICAL MICROBIOLOGY [Internet]. 2007;45(9):2971–8. Available from:

https://journals.asm.org/journal/jcm

58.   CDC Global Health - Kenya - Blog: Giving Blood, Giving Life [Internet]. [cited 2022 Feb

8].   Available   from:

https://www.cdc.gov/globalhealth/countries/kenya/blog/giving.htm

59.   Tunnage J, Yates A, Nwoga C, Sing'oei V, Owuoth J, Polyak CS, et al. Hepatitis and

tuberculosis testing are much less common than HIV testing among adults in Kisumu,

Kenya: results from a cross-sectional assessment. BMC Public Health [Internet]. 2021

Dec 1 [cited 2022 Mar 15];21(1):1–10. Available from:

https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-021-11164-2

60.   Nosocomial Outbreak of Hepatitis B Virus Infection in a Pediatric Hematology and

Oncology Unit in South Africa: Epidemiological Investigation and Measures to Prevent

Further Transmission. 2015;

61.   Thompson P, Morgan CE, Ngimbi P, Mwandagalirwa K, Ravelomanana NLR, Tabala M,

et al. Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant

women and their neonates in the Democratic Republic of the Congo: a feasibility study.

The Lancet Global Health. 2021 Nov 1;9(11):e1600–9.

62.   Abdulkadir Hassan-Kadle M, Sulaiman Osman M, Petrovich Ogurtsov Mohamed

Abdulkadir Hassan-Kadle P, Petrovich Ogurtsov P. Epidemiology of viral hepatitis in

Somalia: Systematic review and meta-analysis study. Available from:

http://dx.doi.org/10.3748/wjg.v24.i34.3927

63.   Kirbak ALS, Ng'ang'a Z, Omolo J, Idris H, Usman A, Mbabazi WB. Sero-prevalence for

Hepatitis B virus among pregnant women attending antenatal clinic in Juba Teaching

Hospital, Republic of South Sudan. Pan Afr Med J [Internet]. 2017 Feb 20 [cited 2022

Feb 22];26. Available from: https://pubmed.ncbi.nlm.nih.gov/28451049/

64.   Ochwoto M, Kimotho JH, Oyugi J, Okoth F, Kioko H, Mining S, et al. Hepatitis B infection

is highly prevalent among patients presenting with jaundice in Kenya. BMC Infectious

Diseases. 2016 Mar 1;16(1).

65.   Oyaro M, Wylie J, Chen CY, Ondondo RO, Kramvis A. Human immunodeficiency virus

infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-

infections among drug users in three major Kenyan cities. Southern African Journal of

HIV Medicine. 2018;19(1).

66.   Kenya | UNAIDS [Internet]. [cited 2022 Feb 22]. Available from:

https://www.unaids.org/en/regionscountries/countries/kenya

67.   eEML - Electronic Essential Medicines List [Internet]. [cited 2022 Feb 22]. Available

from: https://list.essentialmeds.org/?query=tenofovir%20disoproxil%20fumarate

68.   Hepatitis B (HepB3) immunization coverage among 1-year-olds (%) [Internet]. [cited

2022   Feb   16].   Available   from:

https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hepatitis-b-

(hepb3)-immunization-coverage-among-1-year-olds-(-)

Supporting information

756   **S1 Fig: Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) 2020**

757   **statement checklist**

758   **S2 Fig: Joanna Briggs critical appraisal checklist**.

Figure 1

Figure 2

Author (Year)	Participants	HBV cases	Prevalence	95%-CI
Very high risk for HBV				
Ochwoto (2016)	332	167	50.60	[45.22; 55.98]
Atina (2004)	60	18	30.00	[18.40; 41.60]
Muchiri (2013)	100	13	13.00	[6.41; 19.59]
Common effect model			34.94	[31.01; 38.86]
Random effects model			31.29	[9.50; 53.09]
Heterogeneity: $I^2 = 97\%$, $\tau^2 = 353.3752$, $p < 0.01$				
High risk for HBV				
Jepkemei (2020)	112	10	9.80	[4.29; 15.31]
Wahome (2016)	525	42	8.00	[5.68; 10.32]
Day (2013)	159	11	7.00	[3.03; 10.97]
Webale (2015)	752	39	5.20	[3.61; 6.79]
Oyaro (2018)	673	28	4.30	[2.77; 5.83]
Common effect model			5.56	[4.61; 6.52]
Random effects model			6.17	[4.40; 7.94]
Heterogeneity: $I^2 = 59\%$, $\tau^2 = 2.2417$, $p = 0.04$				
Moderate risk for HBV				
Greer (2017)	105	11	11.00	[5.02; 16.98]
Kim (2011)	389	26	6.90	[4.38; 9.42]
Harania (2008)	357	22	6.20	[3.70; 8.70]
Muriuki (2013)	290	17	6.20	[3.42; 8.98]
Maina (2017)	190	11	5.80	[2.48; 9.12]
Salyani (2021)	208	12	5.80	[2.62; 8.98]
Njuguna (2015)	322	3	1.00	[-0.09; 2.09]
Common effect model			3.40	[2.59; 4.21]
Random effects model			5.58	[3.46; 7.70]
Heterogeneity: $I^2 = 87\%$, $\tau^2 = 5.8452$, $p < 0.01$				
Low risk for HBV				
Bartonjo (2019)	594	33	5.60	[3.75; 7.45]
Kisangau (2019)	295	13	4.50	[2.13; 6.87]
Ngaira (2016)	287	10	3.80	[1.59; 6.01]
Onyango (2018)	1215	42	3.50	[2.47; 4.53]
Awili (2020)	1000	34	3.40	[2.28; 4.52]
Wamamba (2017)	2046	63	3.10	[2.35; 3.85]
Aluora (2020)	300	6	2.30	[0.60; 4.00]
Ly (2016)	1091	22	2.10	[1.25; 2.95]
Common effect model			3.11	[2.70; 3.52]
Random effects model			3.31	[2.62; 4.01]
Heterogeneity: $I^2 = 56\%$, $\tau^2 = 0.5239$, $p = 0.03$				

Figure 3

Figure 4

Figure 5